Brokerages predict that Pfenex Inc. (NASDAQ:PFNX) will report sales of $2.83 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Pfenex’s earnings. The highest sales estimate is $3.88 million and the lowest is $1.00 million. Pfenex posted sales of $2.81 million in the same quarter last year, which suggests a positive year-over-year growth rate of 0.7%. The company is scheduled to report its next earnings results on Thursday, August 13th.

On average, analysts expect that Pfenex will report full-year sales of $22.23 million for the current fiscal year, with estimates ranging from $3.00 million to $32.09 million. For the next financial year, analysts anticipate that the business will report sales of $68.37 million, with estimates ranging from $56.00 million to $85.12 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Pfenex.

Pfenex (NASDAQ:PFNX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.05). The firm had revenue of $0.68 million during the quarter, compared to analyst estimates of $3.75 million.

Separately, BidaskClub lowered Pfenex from a “buy” rating to a “hold” rating in a research note on Thursday, April 9th.

Shares of Pfenex stock traded up $0.45 during trading hours on Friday, hitting $7.31. The company’s stock had a trading volume of 355,300 shares, compared to its average volume of 342,727. Pfenex has a twelve month low of $5.26 and a twelve month high of $14.00. The firm has a fifty day moving average of $6.70 and a 200-day moving average of $9.77.

About Pfenex

Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.

Read More: Index Funds

Get a free copy of the Zacks research report on Pfenex (PFNX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with's FREE daily email newsletter.